Interaction Checker

Méthylnaltrexone : interactions médicamenteuses

Méthylnaltrexone (Relistor), antagoniste des opioïdes, présente 52 interactions documentées dans les notices FDA et les fiches d'information que nous indexons : 43 de niveau majeur, 2 de niveau modéré, 0 de niveau mineur et 7 cas où une notice ne signale aucune interaction significative. Chaque entrée ci-dessous cite la phrase sur laquelle elle repose. Cette page consacrée à un médicament est un point de départ, pas un verdict sur votre situation.

Interactions d'après la notice

Interactions majeures (43)

  • Alvimopanantagoniste des opioïdesMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • Belladone et opiumopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • Bictégravir, emtricitabine et ténofovir alafénamideantirétroviralMajeure

    Opioid Antagonist: Naloxegol ↑ naloxegol Avoid use with BIXLENVO; if unavoidable, decrease the dosage of naloxegol and monitor for adverse reactions. (notice Bictégravir, emtricitabine et ténofovir alafénamide, Interactions médicamenteuses)

  • BuprénorphineopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • Buprénorphine et naloxoneopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • Butalbital, aspirine, caféine et codéinebarbituriqueMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • Butalbital, paracétamol, caféine et codéinebarbituriqueMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • ButorphanolopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • CodéineopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • DarunavirantirétroviralMajeure

    John's wort ( Hypericum perforatum ) Hepatitis C direct acting antiviral: elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam Co-administration of PREZISTA/ritonavir… (notice Darunavir, Contre-indications)

  • Darunavir et cobicistatantirétroviralMajeure

    John's wort ( Hypericum perforatum ) Hepatitis C direct acting antiviral: elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam PREZCOBIX or PREZCOBIX PED is… (notice Darunavir et cobicistat, Contre-indications)

  • ÉluxadolineopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • FentanylopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • HydrocodoneopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • Hydrocodone et chlorphénamineopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • Hydrocodone et homatropineopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • Hydrocodone et ibuprofèneopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • Hydrocodone et paracétamolopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • HydromorphoneopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • LénacapavirantirétroviralMajeure

    Opioid Antagonist: naloxegol ↑ naloxegol Avoid use with SUNLENCA; if unavoidable, decrease the dosage of naloxegol and monitor for adverse reactions. (notice Lénacapavir, Interactions médicamenteuses)

  • LévorphanolopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • MéthadoneopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • MorphineopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • NalbuphineopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • Naldémédineantagoniste des opioïdesMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • Nalméfèneantagoniste des opioïdesMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • Naloxégolantagoniste des opioïdesMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • Naloxoneantagoniste des opioïdesMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • Naltrexoneantagoniste des opioïdesMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • Naltrexone et bupropionantagoniste des opioïdesMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • Nirmatrelvir et ritonavirantiviralMajeure

    …Migraine medications: eletriptan, ubrogepant • Mineralocorticoid receptor antagonists: finerenone • Non-opioid analgesic (selective blocker of Na v 1.8 sodium channels): suzetrigine • Opioid antagonists: naloxegol • PDE5 inhibitor: sildenafil (Revatio ® ) when used for pulmonary arterial hypertension (PAH) • Sedative/hypnotics: triazolam, oral midazolam • Serotonin… (notice Nirmatrelvir et ritonavir, Contre-indications)

  • OlicéridineopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • OxycodoneopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • Oxycodone et paracétamolopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • OxymorphoneopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • Paracétamol et codéineopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • Pentazocine et naloxoneopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • PéthidineopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • Prométhazine et codéineopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • RémifentanilopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • TapentadolopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • TramadolopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • Tramadol et paracétamolopioïdeMajeure

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (notice Méthylnaltrexone, Interactions médicamenteuses)

Interactions modérées (2)

  • ÉtravirineantirétroviralModérée

    Narcotic analgesics/treatment of opioid dependence: buprenorphine buprenorphine/naloxone methadone ↔ etravirine ↓ buprenorphine ↔ norbuprenorphine ↔ methadone Etravirine and buprenorphine (or buprenorphine/naloxone) can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as buprenorphine (or buprenorphine/naloxone)… (notice Étravirine, Interactions médicamenteuses)

  • Lofexidineagoniste alpha-adrénergiqueModérée

    Oral Naltrexone : Concomitant use may reduce efficacy of oral naltrexone. (notice Lofexidine, Interactions médicamenteuses)

Aucune interaction significative signalée (7)

  • AcamprosateAucune interaction

    The pharmacokinetics of acamprosate are not affected by alcohol, diazepam, or disulfiram, and clinically important interactions between naltrexone and acamprosate were not observed [ see Clinical Pharmacology ( 12.3 ) ]. (notice Acamprosate, Interactions médicamenteuses)

  • Bromphéniramine, pseudoéphédrine et dextrométhorphaneantihistaminiqueAucune interaction

    Drugs Metabolized by Cytochrome P450 Isozymes In healthy subjects, a subcutaneous dose of 0.3 mg/kg of RELISTOR did not significantly affect the metabolism of dextromethorphan, a CYP2D6 substrate. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • Dextrométhorphanemédicament sérotoninergiqueAucune interaction

    Drugs Metabolized by Cytochrome P450 Isozymes In healthy subjects, a subcutaneous dose of 0.3 mg/kg of RELISTOR did not significantly affect the metabolism of dextromethorphan, a CYP2D6 substrate. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • Dextrométhorphane et quinidinemédicament sérotoninergiqueAucune interaction

    Drugs Metabolized by Cytochrome P450 Isozymes In healthy subjects, a subcutaneous dose of 0.3 mg/kg of RELISTOR did not significantly affect the metabolism of dextromethorphan, a CYP2D6 substrate. (notice Méthylnaltrexone, Interactions médicamenteuses)

  • Elvitégravir, cobicistat, emtricitabine et ténofovirantirétroviralAucune interaction

    Narcotic Analgesics: buprenorphine/ naloxone ↑ buprenorphine ↑ norbuprenorphine ↓ naloxone No dosage adjustment of buprenorphine/naloxone is required upon coadministration with GENVOYA. (notice Elvitégravir, cobicistat, emtricitabine et ténofovir, Interactions médicamenteuses)

  • Emtricitabine et ténofovirantirétroviralAucune interaction

    No clinically significant drug interactions have been either observed or are expected when DESCOVY is combined with the following drugs: buprenorphine, itraconazole, ketoconazole, lorazepam, methadone, midazolam, naloxone, norbuprenorphine, norgestimate/ethinyl estradiol, and sertraline. (notice Emtricitabine et ténofovir, Interactions médicamenteuses)

  • Prométhazine et dextrométhorphaneantihistaminiqueAucune interaction

    Drugs Metabolized by Cytochrome P450 Isozymes In healthy subjects, a subcutaneous dose of 0.3 mg/kg of RELISTOR did not significantly affect the metabolism of dextromethorphan, a CYP2D6 substrate. (notice Méthylnaltrexone, Interactions médicamenteuses)

Vérifiez Méthylnaltrexone avec tout ce que vous prenez. Ajoutez votre liste complète ; toutes les paires sont vérifiées en une fois.

Ouvrir dans le vérificateur

Ceci n'est pas un avis médical. Le niveau de gravité reflète la formulation de la notice, pas votre situation. Une alerte « majeure » peut être courante sous surveillance et une alerte « mineure » peut compter à forte dose. Demandez conseil à un pharmacien.